A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer

Gastric Cancer

Volumn 14, Issue 4, 2011, Pages 339-352

  Chen, Hui ^a   Chen, Lili ^a   Sun, Lingyu ^a   Zhen, Hongqun ^a   Li, Xiaomei ^a   Zhang, Qifan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Gastric cancer; KLF6 SV1; RNA interference; Tumor gene therapy

Indexed keywords

GELATINASE B; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL KINASE; POLYETHYLENEIMINE; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA; UVOMORULIN; VASCULOTROPIN;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE IDENTIFICATION; GENE SILENCING; GENE TARGETING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KRUPPEL LIKE FACTOR 6 GENE; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; STOMACH CARCINOGENESIS; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; ANIMALS; APOPTOSIS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INJECTIONS, INTRALESIONAL; KI-67 ANTIGEN; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; MIDDLE AGED; POLYETHYLENEIMINE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84855641952     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0049-x     Document Type: Article

References (48)

1. Gordon DL. Tumors of the stomach. In: Feldman M, editor. Gastrointestinal and liver disease: Pathophysiology, diagnosis, management. Philadelphia: WB Saunders; 2005. p. 733-57.
2. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev. 2000;26:243-55. (Pubitemid 30604036)
3. Ushijima T, Sasako M. Focus on gastric cancer. Cancer Cell. 2004;5:121-5. (Pubitemid 38283798)
4. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and Kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol. 2001;188:143-60. (Pubitemid 32622905)
5. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, et al. KLF6, a candidate tumour suppressor gene mutated in prostate cancer. Science. 2001;294:2563-6. (Pubitemid 34027299)
6. Chen C, Hyytinen ER, Sun X, Helin HJ, Koivisto PA Jr, Frierson HF, et al. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol. 2003;162:1349-54. (Pubitemid 36350678)
7. Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S, et al. Kruppel-like factor 6 (KLF6) is a tumour suppressor gene frequently inactivated in colorectal cancer. Gastroenterology. 2004;126:1090-3.
8. Cho YG, Choi BJ, Kim CJ, Song JW, Kim SY, Nam SW, et al. Genetic alterations of the KLF6 gene in colorectal cancers. APMIS. 2006;114:458-64.
9. Ito G, Uchiyama M, Kondo M, Usami SMN, Maeda O, Kawabe T, et al. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in nonsmall cell lung cancer cells. Cancer Res. 2004;64:3838-43. (Pubitemid 38697293)
10. DiFeo A, Feld L, Rodriguez E, Wang C, Beer DG, Martignetti JA, et al. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Res. 2008;68:965-70. (Pubitemid 351272212)
11. Cho YG, Kim CJ, Park CH, Yang YM, Kim SY, Nam SW, et al. Genetic alterations of the KLF6 gene in gastric cancer. Oncogene. 2005;24:4588-90. (Pubitemid 41032622)
12. Jeng YM, Hsu HC. KLF6, a putative tumour suppressor gene, is mutated in astrocytic gliomas. Int J Cancer. 2003;105:625-9.
13. Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, Singh G, et al. Functional inactivation of the KLF6 tumour suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. Int J Cancer. 2007;121:1390-5. (Pubitemid 47293811)
14. Chen HK, Liu XQ, Lin J, Chen TY, Feng QS, Zeng YX. Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas. Ai Zheng. 2002;21:1047-50.
15. Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, et al. Frequent inactivation of the tumour suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology. 2004;40:1047-52. (Pubitemid 39425559)
16. Pan XC, Chen Z, Chen F, Chen XH, Jin HY, Xu XY. Inactivation of the tumour suppressor Kruppel-like factor 6 (KLF6) by mutation or decreased expression in hepatocellular carcinomas. J Zhejiang Univ Sci B. 2006;7:830-6.
17. Song J, Kim CJ, Cho YG, Kim SY, Nam SW, Lee SH, et al. Genetic and epigenetic alterations of the KLF6 gene in hepatocellular carcinoma. J Gastroenterol Hepatol. 2006;21:1286-9. (Pubitemid 44034342)
18. Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol. 2007;46:645-54. (Pubitemid 46400140)
19. Hartela M, Narla G, Wente MN, Giese NA, Martignoni ME, Martignetti JA, et al. Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. Eur J Cancer. 2008;44:1895-903.
20. DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, et al. Role of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res. 2006;12:3730-9. (Pubitemid 44000254)
21. Narla G, DiFeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 2005;65: 1213-22. (Pubitemid 40270146)
22. Teixeira MS, Camacho-Vanegas O, Fernandez Y, Narla G, DiFeo A, Lee B, et al. KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. Int J Cancer. 2007;121:1976-83. (Pubitemid 47463160)
23. Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res. 2005;65:5761-8. (Pubitemid 40911179)
24. Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, et al. KLF-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest. 2008;118:2711-21.
25. Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, Choudhri A, et al. Functional role of the KLF6 tumour suppressor gene in gastric cancer. Eur J Cancer. 2009;45:666-76.
26. Difeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G, et al. KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. Cancer Res. 2009;69:4733-41.
27. Fan KX, Dai JX, Wang H, Wei HF, Cao ZG, Hou S, et al. Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum. 2008;58: 2041-52. (Pubitemid 351988096)
28. Mehlen P, Puisieux A. Metastasis: A question of life or death. Nat Rev Cancer. 2006;6:449-58.
29. Igney FH, Krammer PH. Death and anti-death: Tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277-88. (Pubitemid 37328781)
30. DiFeo A, Martignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat. 2009;12:1-7.
31. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13: 1899-911. (Pubitemid 29407357)
32. Kroemer G. Mitochondrial control of apoptosis: An overview. Biochem Soc Symp. 1999;66:1-15. (Pubitemid 129639017)
33. Zha J, Harada H, Osipov K, Jockel J, Waksman G, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-xl. Cell. 1996;87:619-28. (Pubitemid 26386936)
34. Wang J, Yang J, Kuropatwinski K, Wang W, Liu XQ, Hauser J, et al. Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res. 2008;68:3152-60.
35. Jia SF, Worth LL, Densmore CL, Xu B, Zhou Z, Kleinerman ES. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther. 2002;9:260-6. (Pubitemid 34205500)
36. Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS, et al. Cyclin dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res. 2004;64:3885-91. (Pubitemid 38697300)
37. Slavin DA, Koritschoner NP, Prieto CC, Lopez-Diaz FJ, Chatton B, Bocco JL. A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-jun proto-oncoprotein function. Oncogene. 2004;23:8196-205. (Pubitemid 39531831)
38. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science. 1998;281:1305-8. (Pubitemid 28406815)
39. Bartke T, Siegmond D, Peters N, Reichwein M, Henkler F, Scheurich P, et al. p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene. 2001;20:571-80. (Pubitemid 32156181)
40. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell. 2001;20:812-8.
41. Zhang L, Ming L, Yu J. BH3mimetics to improve cancer therapy: Mechanisms and examples. Drug Resist Updat. 2007;10:207-17. (Pubitemid 351163146)
42. Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU, Brady JN. Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene. 2005;24:6719-28. (Pubitemid 41486802)
43. Tang ED, Nuñez G, Barr FG, Guan KL. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem. 1999;274:16741-6.
44. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med. 2005;11:50-5. (Pubitemid 40215837)
45. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA. 2008;105: 11915-20.
46. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: A progress report on siRNA based therapeutics. Nat Rev Drug Discov. 2007;6:443-53. (Pubitemid 47064567)
47. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther. 2006;13:464-77.
48. Boussif O, Lezoualc'h F, Zanta A, Mergny MD, Scherman D, Demeneix B, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci USA. 1995;92:7297-301.